![]() |
|
|
Vol. 63, Issue 3, 489-498, March 2003
Department of Physiology, University of Arizona, Tucson, Arizona (D.B., S.H.W.); and Computational Chemistry and Molecular Structure Research, Eli Lilly and Co., Indianapolis, Indiana (S.E., J.H.W.)
| |
Abstract |
|---|
|
|
|---|
Organic cation transporters play a critical role in the elimination of therapeutic compounds in the liver and the kidney. We used computational quantitative structure activity approaches to predict molecular features that influence interaction with the human ortholog of the organic cation transporter (hOCT1). [3H]tetraethylammonium uptake in HeLa cells stably expressing hOCT1 was inhibited to varying extents by a diverse set of 30 molecules. A subset of 22 of these was used to produce, using Catalyst, a pharmacophore that consisted of three hydrophobic features and a positive ionizable feature. The correlation coefficient of observed versus predicted IC50 was 0.86 for this training set, which was superior to calculated logP alone (r = 0.73) as a predictor of hOCT1 inhibition. A descriptor-based quantitative structure-activity relationship study using Cerius2 resulted in an equation relating five molecular descriptors to log IC50 with a correlation coefficient of 0.95. Furthermore, a group of phenylpyridinium and quinolinium compounds were used to investigate the spatial limitations of the hOCT1 binding site. The affinity for hOCT was higher for 4-phenylpyridiniums > 3-phenylpyridiniums > quinolinium, indicating that substrate affinity was influenced by the distribution of hydrophobic mass. In addition, supraplanar hydrophobic mass was found to increase the affinity for binding hOCT1. These results indicate how a combination of computational and in vitro approaches may yield insight into the binding affinity of transporters and may be applicable to predicting these properties for new therapeutics.
| |
Introduction |
|---|
|
|
|---|
The
transepithelial transport of organic cations (OCs) plays an important
role in the excretion of xenobiotic compounds from the body by means of
the liver and kidney, and from the cerebrospinal fluid via the choroid
plexus (Pritchard and Miller, 1993
). The proteins involved in the
translocation of OCs transport a broad range of substrates. These
substrates include naturally occurring plant alkaloids and synthetic
drugs such as cimetidine and procainamide. These chemicals are not only
therapeutically diverse but show remarkable structural diversity as
well. A characterization of the structural parameters of substrates
translocated by organic cation transporters may provide insight into
the molecular determinants of substrate specificity (Ullrich, 1999
).
Because the elimination of many therapeutic drugs is significantly
influenced by the interaction of these compounds with OC transporters,
information pertinent to predicting the kinetics of such interactions
may be useful in estimating the pharmacokinetics of a broad range of pharmaceuticals.
The organic cation transporter, OCT1, is likely to play a significant
role in the elimination of a variety of therapeutic compounds. OCT1 is
highly expressed in the sinusoidal membrane of liver cells
(Meyer-Wentrup et al., 1998
), where it is presumed to play a role in
the hepatic metabolism and elimination of cationic drugs (Koepsell,
1998
). In the rat, OCT1 is also expressed in the basolateral membrane
of early (S1 segment) renal proximal tubule (Karbach et al., 2000
),
where it is presumed to play a role in the peritubular uptake step of
OC secretion.
With the increasing number of discoveries of new molecules that
interact with OC transporters (Zhang et al., 2000
; Dresser et al.,
2001
), understanding the three-dimensional features fundamental to
molecular interaction with the transporter is desirable. Hydrophobicity and basicity have been suggested to be the principal determinants of
substrate interaction with OC transporters on both the apical and
basolateral membranes of the rat renal proximal tubule (Ullrich et al.,
1991
). This observation was independently supported for apical and
basolateral transporters in the rabbit (Groves et al., 1994
; Wright et
al., 1995
; Wright and Wunz, 1999
). However, the mechanisms of substrate
interaction with proteins possessing multiple transmembrane domains are
difficult to assess directly because of the absence of crystal
structures for these proteins. It is therefore desirable to take
advantage of computational techniques such as three-dimensional
quantitative structure-activity relationships (3D-QSAR) that may
provide an effective means of assessing the basis of
substrate-transporter interaction in the absence of knowledge of the 3D
structure of the transport protein. Structure-activity relationships
have been developed previously for substrates of the
OC+/H+ exchanger (Wright
and Wunz, 1999
). Using this analysis, it was concluded that the binding
site of the luminal transport step of rabbit renal proximal tubules,
the OC+/H+ exchanger,
includes a planar hydrophobic surface sufficiently accommodating that
no steric exclusion is evident when a planar (9- × 12-Å) hydrophobic
mass is rotated about an N-pyridinium center. This work,
although comparatively rudimentary, introduced the use of
structure-activity relationship analysis as a way to understand how
therapeutics may interact with OC transporters.
In the present report, multiple QSAR approaches were used to assess the influence of selected structural and physical factors on substrate interaction with the human organic cation transporter, hOCT1. The first technique involved development of a computationally derived pharmacophore, a three-dimensional arrangement of important molecular features, based on the interaction of a structurally diverse set of OC inhibitors with hOCT1, complemented by a descriptor-based QSAR model that provided further insight into molecular interaction with the transporter. The descriptor-based computational analysis provided the basis for an empirical assessment of substrate-transporter interaction that used a strategically modified set of inhibitors to validate parameters identified in the descriptor-based analysis.
| |
Materials and Methods |
|---|
|
|
|---|
Materials.
[3H]Tetraethylammonium
([3H]TEA; 13.2 Ci/mmol) was a custom synthesis
by Amersham Biosciences (Piscataway, NJ).
[3H]1-Methyl-4-phenylpyridinium (80 Ci/mmol)
was purchased from ARC, Inc. (St. Louis, MO). NBD-TMA was synthesized
as described previously (Bednarczyk et al., 2000
) (and is commercially
available from Macrocyclics, Inc., TX). The phenylpyridinium and
quinolinium analogs were synthesized as described previously (Wright et
al., 1995
). Other chemicals were purchased from Sigma Chemical Corp. (St. Louis, MO) or Aldrich Chemical Co. (Milwaukee, WI). Octanol/water partition coefficients (Log P) were calculated using CLOGP software (Daylight Chemical Information Systems; www.daylight.com).
Generation, Transfection, and Culture of HeLa Cells Expressing hOCT1 and hOCT1-V5His cDNAs. The hOCT1 cDNA in the pEXO vector was kindly provided by Dr. Kathleen M. Giacomini (University of California, San Francisco, CA). hOCT1 was removed from pEXO using KpnI and XhoI and ligated into pIZ-V5His (Invitrogen, Carlsbad, CA). hOCT1 was removed from pIZ-V5His at HindIII and XhoI and ligated into pcDNA3.1 to generate a plasmid for production of wild-type hOCT1. Because of a future interest in isolating hOCT1 protein from cells, we generated a histidine-tagged hOCT1 sequence by muting the stop codon and introducing a frame shift mutation to interpose an alanine in frame with the V5His tag of the vector, pIZ-V5His. This was accomplished using the following primers: the OpIE2 promoter site on the plasmid was used as the forward primer (5'-CGCACCGATCTGGTAAACAC-3') and 5'-GCCCTCTAGACTCGAGGCGGTGCCCGAGGGTTC-3' as the reverse primer containing the mutated sequence. The mutated PCR fragment was cut at HindIII and XhoI to generate a full-length cDNA sequence that was ligated back into the parent vector. Another mutation was performed on the pIZ-hOCT1-V5His sequence to insert an EcoRI cut site after the stop codon of the His-tag using the reverse primer 5'-GGATTTAGTCAGATGAATTCAATGGTGATG-3', in conjunction with the forward primer for the OpIE2 promoter priming site on the plasmid. The resulting PCR fragment was digested with HindIII and EcoRI and ligated into pUC18, from which it was digested with BamHI and EcoRI and ligated into pcDNA3, creating pcDNA3-hOCT1-V5His. All DNA sequencing was performed by the Arizona Research Laboratory-Laboratory of Molecular Systematics and Evolution (University of Arizona, Tucson, AZ).
The pcDNA3-hOCT1-V5His was linearized with PvuI and transfected into HeLa cells using Effectine (QIAGEN, Valencia, CA) according to the manufacturer's instructions (with the exception that we used a cDNA-to-enhancer ratio of 1:8, mass/volume). Transfected cells were plated at ~50% confluence and the medium was changed 18 to 24 h later. At 72 h after transfection, the HeLa cells were exposed to, and thereafter continuously grown in, culture media containing 400 µg/ml G418 (Inivtrogen) to select for cells that had incorporated the cDNA construct. To select cells stably expressing OCT1 transport activity, the cells were exposed to 20 µM NBD-TMA, a fluorescent organic cation (or a pH-insensitive derivative of NBD-TMA (Bednarczyk et al., 2000Fluorescence of NBD-TMA+ Loaded Cells. HeLa cells stably transfected with pcDNA3-hOCT1-V5His were loaded with 10 to 20 µM NBD-TMA in Waymouth buffer (135 mM NaCl, 13 mM HEPES, 2.5 mM CaCl2, 1.2 mM MgCl2, 0.8 mM MgSO4, 5 mM KCl, and 28 mM glucose) for 5 to 30 min. The solution was then aspirated and the cells were rinsed with Waymouth buffer plus 100 to 250 µM TPrA and maintained in this solution during fluorescence microscopy.
Measurement of Transport.
After aspiration of the culture
medium, the cells in each well of a 12-well plate were twice exposed,
each time for 15 min, to 1 ml of Waymouth buffer at room temperature.
After the second 15-min incubation, the buffer was aspirated and
Waymouth buffer containing 1 µCi/ml [3H]TEA,
with or without inhibitor, was added. After a prescribed interval, the
buffer containing radiolabeled substrate was aspirated and the cells
were washed twice with 1 ml of ice-cold Waymouth buffer. The cells were
then solubilized with 1 ml of 0.2 N NaOH and 1% SDS. This solution was
pipetted repeatedly until homogenous, then neutralized with 200 µl of
1 N HCl. Ten milliliters of scintillation cocktail were then added to
this homogenate, and radioactivity in the resulting solution was
counted in a scintillation counter. The cells in each of three
additional wells were counted using a cell counter (Beckman Coulter,
Fullerton, CA) and the counts averaged to determine the number of cells
per well (routinely 1.0-1.2 million cells/well). Cells in three
additional wells were solubilized with 1 ml of 0.2 N NaOH later
neutralized with 200 µl of 1 N HCl and used to determine the average
protein content of each well (Bio-Rad, Hercules, CA). The concentration
of inhibitor that reduced uptake by 50% (IC50)
was generated using Sigma Plot by fitting the data to the following
equation (Groves et al., 1994
): J = [(Japp
[T])/(IC50 + [I])] + C, where
J is the uptake of [3H]TEA;
Japp is a constant related to the
product of the maximal rate of TEA uptake and the ratio of the
inhibitor IC50 and the Kt for TEA transport; [T] is the
concentration of [3H]TEA; [I] is the
inhibitor concentration, and C is a constant representing
the nonsaturable component of [3H]TEA uptake.
Modeling with Catalyst and Cerius2. The computational molecular modeling studies were carried out using Silicon Graphics Octane workstations (SGI, Mountain View, CA). The 3D structures of substrates were built interactively using either Catalyst version 3.1 or 3.4. (Accelrys, San Diego, CA) and used to generate a 3D-QSAR model. The number of conformers generated for each substrate was limited to a maximum of 255 with an energy range of 20 kcal/mol. Ten hypotheses were generated using conformers for the 22 molecules in the training set and the IC50 values, after manual selection of the hydrogen bond donor, hydrogen bond acceptor, hydrophobic, and negative ionizable pharmacophoric features. After assessing all 10 hypotheses generated, the lowest energy cost hypothesis was considered the best. The goodness of the structure-activity correlation was estimated from calculated r values. Statistical significance of the retrieved hypothesis was verified by permuting the response variable; i.e., the activities of the training set compounds were mixed a number of times (so that each value was no longer assigned to the original molecule) and the Catalyst hypothesis generation procedure was repeated. Multiple conformations of the eight molecules in the test set were generated using the same method as the training set before fitting the conformers to the pharmacophore to generate a prediction.
Cerius2 (Accelrys) was used to generate more than 200 molecular descriptors for the 30 molecules used in the Catalyst studies. The forward stepwise regression method incorporated within Cerius2 was then used to relate the log IC50 to a selection of these descriptors, and hence result in a QSAR model. The model was validated for numerical stability and internal consistency using both the leave-one-out cross-validation method and by permuting, or randomizing, the response variable.| |
Results |
|---|
|
|
|---|
hOCT1 Sequence Variation and Stable Cell Line Characteristics.
The sequence of the hOCT1 cDNA provided by K. Giacomini differed by one
base from the sequence reported by Zhang et al. (1997)
(Genbank
accession number U77086). That difference was a guanine, rather than an
adenine, at nucleotide 1275. The resulting codon encoded a valine
rather than a methionine at amino acid 408. The sequence of an hOCT1
fragment (from position 1197 to 1588), amplified using RT-PCR from
human renal mRNA, confirmed the presence of G at position 1275 (i.e.,
valine at amino acid 408) in a sequence that otherwise matched that of
Zhang et al. (1997)
. The full-length cDNA coding for hOCT1, as provided
by Dr. Giacomini, was therefore used for the preparation of the
hOCT1-V5His construct employed in the studies described below.
|
1 5 min
1.
These values are comparable with those reported by Zhang et al. (1998)
|
|
Pharmacophore 3D-QSAR Generation.
We next used a computational
approach to develop QSARs and a predictive model of inhibitor/hOCT1
interaction. The commercial software program Catalyst was used to model
the structural features that facilitate interaction of inhibitors at
the hOCT1 binding site. A set of chemically diverse molecules with
IC50 values for hOCT1 spanning more than 3 orders
of magnitude (Table 2) was used for
pharmacophore construction. These 22 molecules identified a
pharmacophore with four features of interaction with the transporter. The four features included a positive ionizable feature and three hydrophobes at distances of 5.12, 4.19, and 5.32 Å from the center of
the positive ionizable feature (Fig. 3A).
Regression of the logs of experimentally determined and the estimated
IC50 values for the compounds contributing to the
model resulted in a correlation coefficient of 0.86 (Fig.
4,
; Table 2). Compounds with the highest apparent affinity for the transporter (i.e., those with the
lowest IC50 values) generally possessed the
greatest number of pharmacophore features, whereas compounds with
structures that included fewer of these features generally showed a
lower apparent affinity for the transporter. This can be seen in Fig.
3B, where the most potent inhibitor, clonidine,
(IC50 = 0.71 µM) is characterized by all four
pharmacophore features, but the least potent inhibitor, choline
(IC50 = 3.5 mM), is described by only one of the
features, (i.e., the positive ionizable feature) (Fig. 3C).
Additionally, choline has a hydrogen bond donor near two of the
hydrophobes, perhaps contributing to its failure to inhibit TEA
transport to a significant degree. Although many of the chemical
features of the diverse group of molecules in the training set were in
spatial agreement with the model pharmacophore, some molecular
structures clearly lay outside the area described by the model.
This can be readily seen for ranitidine (IC50 = 21.7 µM; Fig. 3D). Furthermore, there was generally poor correlation
(r = 0.54) between the Catalyst-produced estimates of
IC50 and the experimentally determined values for the pyridinium- and quinolinium-based set of substrates described in
the following group of experiments (Fig. 4,
; Table 2).
Nevertheless, the Catalyst-produced model was more accurate than the
often-cited correlation between the hydrophobicity of substrates or
inhibitors and the apparent affinity of OC transporters for these
compounds. Figure 5 shows the
relationship between the log of the IC50 for each
of the members of the training set and their CLog P values. The
correlation (r = 0.73) was less than that of the
Catalyst model (r = 0.86), which may reflect the
substantial variation in the three dimensional structure of several
inhibitors with similar CLog P values. Indeed, when a structurally
homologous group of molecules is examined (e.g., the nTAAs), the
correlation between hydrophobicity and apparent affinity for hOCT1 can
be quite striking (Fig. 5,
).
|
|
|
|
Descriptor-Based QSAR Generation.
Previous work has shown that
a descriptor-based QSAR model generated using
Cerius2 can be superior in its ability to predict
activity parameters than a Catalyst-derived model (Ekins and Obach,
2000
). Consequently, a descriptor-based QSAR model for hOCT1 was built
using the molecular descriptors generated by the
Cerius2 program. The following equation
identifying molecular descriptors found to be correlated with
inhibition of hOCT1 activity was produced using forward stepwise
regression:
|
is
a member of the shadow indices descriptors and is the ratio of largest
to smallest dimension; and Atype_H_52 is the number of times that each
AlogP atom appears in the molecule and is part of the Thermodynamic
family (AlogP_atypes) of descriptors (Viswanadhan et al., 1989
|
Interaction of N-1-Substitued Pyridiniums and
Quinoliniums with hOCT1.
Of the five molecular descriptors
presented in eq. 1, the relative importance of the Shadow-
term
(i.e., the ratio of the largest to the smallest dimension of the
inhibitor) was particularly intriguing. In a previous study, we used a
series of phenylpyridinium and quinolinium compounds to examine the
influence of the spatial distribution of hydrophobic mass on the
interaction of inhibitors with the OC/H+
exchanger of rabbit renal brush border membrane vesicles (Wright and
Wunz, 1999
). Of relevance to the present observations is the fact that
the ratio of the largest to the smallest dimension (Shadow-
values)
of these compounds varies systematically. The QSAR model presented in
eq. 1 suggests that systematic variation of molecular dimension should
have a predictable influence on the interaction of test agents with
hOCT1. Consequently, we elected to investigate the inhibitory efficacy
of a group of phenylpyridinium and quinolinium compounds with ethyl,
hydroxyethyl, or methylphenyl side groups located at the N1 position
(Fig. 7).
|
|
| |
Discussion |
|---|
|
|
|---|
Although the interaction of substrate with OC transporters has
been described for a variety of different compounds (e.g., Dresser et
al., 2001
), such descriptions have usually lacked structural/spatial information with regard to the substrates or transporters.
Structure-related analysis of substrate interaction with cloned OC
transporters has been performed using the nTAAs (Zhang et al., 1999
;
Dresser et al., 2000
). These compounds, however, have limited
structural diversity. In the present study, two groups of chemicals
were employed, one with broad structural diversity and binding affinity for hOCT1, and a second of comparatively limited structural breadth that focused on the influence of a single structural parameter. Both
groups were used to extend the observation that substrate hydrophobicity is a principal determinant of substrate interaction with
OC transporters by identifying distinct structural features that
influence molecular interaction with the human ortholog of the organic
cation transporter, OCT1.
To achieve this, a computational method was used to generate a
pharmacophore reflecting the structural features that maximize substrate-transporter interaction. Such methods use conformers of
ligands to suggest functional groups, the geometry of structural features, regions of favorable/unfavorable electrostatic interaction, or favorable/unfavorable steric interactions that may be essential for
activity or fit to the receptor binding/active site. The combination and 3D spatial distribution of physicochemical properties, the functional groups of the ligands, and a measure of binding site properties of an enzyme, such as the
Km (apparent) (Nelsestuen and
Martinez, 1997
), Ki,
IC50, or other measure, are used to define the
`pharmacophore'. We used the commercial software package, Catalyst,
to develop a pharmacophore for hOCT1 that was based upon the inhibition
of transport activity produced by a structurally diverse array of
molecules. The IC50 values produced by this
training set spanned more than 3 orders of magnitude (Table 2). The
pharmacophore developed from this set of compounds was composed
of one positive ionizable feature and three distinct
hydrophobes, characteristics that are qualitatively consistent with
previously reported observations demonstrating the importance of a
basic nitrogen and a diffuse hydrophobic component(s) for interaction
with organic cation transporters (Ullrich, 1999
; van Montfoort et al.,
2001
;Ullrich, 1997
). The Catalyst-derived pharmacophore also provided
valuable information regarding the geometry of these features relative
to one another, and the resulting model had a strong internal
correlation between measured and predicted IC50
values (r = 0.86). The strong internal correlation
between the measured and the predicted IC50
values reported here for the training set compares favorably with
recently developed Catalyst-derived pharmacophores for another
xenobiotic transporter, P-glycoprotein (Ekins et al., 2002
).
Examination of the values in Fig. 4, however, did reveal some significant discrepancies between measured and predicted IC50 values, especially for members of the several phenylpyridinium compounds in the test set. Although these discrepancies may have reflected, at least in part, the limited structural diversity of the molecules in the test set, significant discrepancies were also noted within the training set (e.g., for amantadine and ranitidine; Table 2). In retrospect, the presence of `outliers' in a pharmacophore-based model is not surprising. The algorithm used to develop a pharmacophore seeks a single, best-fit structure for interaction with a receptor that is expected to possess a marked degree of structural specificity. However, OC transporters do not display the narrow specificity of the typical receptor, which generally accepts a `best' structure to the exclusion of most others. OC transporters in contrast, because of the protective role they play, necessarily must accept a broad array of substrate structures, including compounds to which the host organism may never have been exposed (e.g., a dietary toxin or synthetic drug). Therefore, one might predict a selective advantage arising from a process that can interact effectively with a diverse array of environmental chemicals, making it desirable for OC transporters to accept chemical structures that fit a generalized format, rather than one represented by a classic pharmacophore.
To achieve a computational model with greater predictability, a
descriptor-based QSAR model was subsequently derived using Cerius2. In contrast to the structurally based
pharmacophore approach, the QSAR regression model was based upon
multiple regression of a number of quantitative molecular descriptors.
The final model emphasized the importance of hydrophobic
(ADME_solubility), hydrogen bond donor (S_ssNH), shape (Shadow-
),
and charge (Jurs-RNCS) features. The Cerius2
model had a very high correlation between measured and predicted IC50 values for all 30 molecules evaluated in
this present study (Fig. 6; r = 0.95) and represented a
marked improvement in predictability compared with the Catalyst,
pharmacophore-based model, as well as with previous efforts to
correlate OCT binding to the single physical descriptor, CLogP.
Not surprisingly, greatest weight in the QSAR model was given to a
molecular descriptor associated with hydrophobicity (ADME solubility).
Somewhat unexpected, however, was the next most heavily weighted term,
Shadow-
(ratio of the longest to shortest molecular dimension). This
dimensionality term, Shadow-
, describes a physical parameter not
previously hypothesized to significantly contribute to molecular
interaction with OC transporters. This term clearly distinguishes the
phenylpyridinium and quinolinium compounds included in this study, and
presumably explains the improved correlation of predicted and measured
IC50 values for the test set compounds evident in
the Cerius2 QSAR model (Fig. 6), compared with
the Catalyst pharmacophore model (Fig. 4).
Differences in relative geometric location of planar hydrophobic mass
are intrinsic in the structures of the phenylpyridinium and quinolinium
compounds used in this study. These changes in the geometric location
of planar hydrophobic mass permitted a systematic assessment of the
potential role that steric configuration can play in binding of
substrate to an OC transporter. In fact, although for any chemical
genus tested (i.e., 4-phenyl or 3-phenylpyridinium or quinolinium)
increases in hydrophobicity (introduced through the R-group
at the N1 position) were associated with decreases in
IC50 (Fig. 8), it was also evident that the
location of planar hydrophobic mass had a clear and systematic effect
on inhibitor interaction. For molecules of similar hydrophobicity, the
rank order of apparent affinity for hOCT1 was 4-phenylpyridinium > 3-phenylpyridinium > quinolinium, which corresponded to the
rank order of the mean Shadow-
values for each genus: 2.45 > 2.05 > 1.75, respectively. Although the basis for this effect is
not clear, it may reflect a systematic misalignment of chemical
features, such as the positive charge, with important structural
elements of the binding site, resulting in decreased affinity for the
molecule. Alternatively, the more elongated structure of the
4-phenylpyridiniums may permit association with a more stabilizing
region of the binding site than the foreshortened quinoliniums.
Additionally, it is possible that the hypothesized stabilizing feature
of the protein is fundamental for
-
stacking type interactions
with the phenyl group of the more elongated 4-phenylpyridiniums, and
perhaps this stabilizing feature is misaligned or not adequately
reached by the unsaturated rings within the other two groups of compounds.
Interestingly, the phenylpyridinium and quinolinium compounds used in
the present study produced a very different inhibitor profile in a
previous study on the molecular determinants of substrate interaction
with the OC/H+ exchanger of renal brush border
membranes (Wright and Wunz, 1999
). Whereas for hOCT1, a change in
molecular dimension (basis for the shift in the Shadow-
term)
produced the marked effect on binding site interaction evident in Fig.
8, these structural changes had no effect on interaction with the
OC/H+ exchanger, leading to the suggestion that
the OC/H+ exchanger has a receptor surface that
is, in functional terms, broadly planar in structure (Wright and Wunz,
1999
). The present results suggest that the hOCT1 receptor is not
necessarily represented by a broad plane. In fact, the substantially
higher affinity of hOCT1 for amantadine, compared with cyclohexylamine
(Table 2), suggests that the binding site for hOCT1 may be best
described as a `pocket' that is conducive to establishing hydrophobic
interactions above the previously hypothesized hydrophobic plane.
In summary, a Catalyst-derived pharmacophore confirmed the importance of positive charge and hydrophobicity on binding of substrates to OC transporters and extended upon those observations by providing geometric location of the features relative to one another. A QSAR model derived using Cerius2 reiterated the importance of hydrophobicity and a basic nitrogen to molecular interaction with organic cation transporters. More importantly, the QSAR analysis unveiled a structural parameter (dimensionality) not previously hypothesized to have value in the molecular interaction with an organic cation transporter. The importance of this dimensionality parameter was validated by the empirical test of the effect of the placement of planar hydrophobic mass on binding to hOCT1. The developing view is of an hOCT1 binding site that is most conducive to interaction with comparatively elongated, cationic molecules capable of interacting with a supraplanar stabilizing structure within a hydrophobic pocket of the protein.
| |
Acknowledgments |
|---|
We gratefully acknowledge the assistance Dr. Eugene Mash (University of Arizona Dept. of Chemistry) for his assistance in the synthesis of NBD-TMA and the several phenylpyridinium and quinolinium compounds used in this study.
| |
Footnotes |
|---|
Received July 10, 2002; Accepted November 4, 2002
1 Present address: Concurrent Pharmaceuticals Inc., 502 West Office Center Drive, Fort Washington, PA 19034.
This work was supported in part by National Institutes of Health grants DK58251, ES06694, and HL07249.
Address correspondence to: Stephen H. Wright, Department of Physiology, College of Medicine, University of Arizona, Tucson, AZ 85724. E-mail: shwright{at}u.arizona.edu
| |
Abbreviations |
|---|
OC, organic cation; OCT, organic cation transporter; 3D-QSAR, three-dimensional quantitative structure-activity relationship; TEA, tetraethylammonium; NBD-TMA, [2-(4-nitro-2,1,3-benzoxadiazol-7-yl)aminoethyl]trimethylammonium; PCR, polymerase chain reaction; nTAA, n-tetraalkylammonium; TBA, tetrabutylammonium; TPeA, tetrapentylammonium; TprA, tetrapropylammonium.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
U. G. Schmidt, A. Endler, S. Schelbert, A. Brunner, M. Schnell, H. E. Neuhaus, D. Marty-Mazars, F. Marty, S. Baginsky, and E. Martinoia Novel Tonoplast Transporters Identified Using a Proteomic Approach with Vacuoles Isolated from Cauliflower Buds Plant Physiology, September 1, 2007; 145(1): 216 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Pelis, X. Zhang, Y. Dangprapai, and S. H. Wright Cysteine Accessibility in the Hydrophilic Cleft of Human Organic Cation Transporter 2 J. Biol. Chem., November 17, 2006; 281(46): 35272 - 35280. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Engel and J. Wang Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter Mol. Pharmacol., November 1, 2005; 68(5): 1397 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Schmitt and H. Koepsell Alkali Cation Binding and Permeation in the Rat Organic Cation Transporter rOCT2 J. Biol. Chem., July 1, 2005; 280(26): 24481 - 24490. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Srimaroeng, V. Chatsudthipong, A. G. Aslamkhan, and J. B. Pritchard Transport of the Natural Sweetener Stevioside and Its Aglycone Steviol by Human Organic Anion Transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8) J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 621 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Suhre, S. Ekins, C. Chang, P. W. Swaan, and S. H. Wright Molecular Determinants of Substrate/Inhibitor Binding to the Human and Rabbit Renal Organic Cation Transporters hOCT2 and rbOCT2 Mol. Pharmacol., April 1, 2005; 67(4): 1067 - 1077. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chang, P. W. Swaan, L. Y. Ngo, P. Y. Lum, S. D. Patil, and J. D. Unadkat Molecular Requirements of the Human Nucleoside Transporters hCNT1, hCNT2, and hENT1 Mol. Pharmacol., March 1, 2004; 65(3): 558 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shuralyova, P. Tajmir, P. J. Bilan, G. Sweeney, and I. R. Coe Inhibition of glucose uptake in murine cardiomyocyte cell line HL-1 by cardioprotective drugs dilazep and dipyridamole Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H627 - H632. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||